Journey Medical Corp
No enriched coverage for $DERM in the last 7 days.
No SEC Form 4 filings for $DERM in the last 30 days.
See all $DERM insider activity →Journey Medical Corp (DERM) filed an SEC Form 8-K — Submission of Matters to a Vote of Security Holders. false 0001867066 0001867066 2026-06-24 2026-06-24 iso4217:USD xbrli:shares iso4217:USD xbrli:shares UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of repor
Journey Medical Corp (DERM) is experiencing a period of high volatility, with recent short-term gains but a long-term downward trend. The company's stock performance over the past year shows a significant decline, reflecting skepticism about its growth and financial management despite some analyst "buy" ratings from smaller firms. Investors are advised to be cautious, as the stock sits at an inflection point, requiring clear evidence of sustained revenue growth and operational improvements to justify a higher valuation.
While the top- and bottom-line numbers for Journey Medical (DERM) give a sense of how the business performed in the quarter ended September 2025, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.
Recent DERM coverage spans financial news and corporate actions.
Routine corporate governance outcomes; unlikely to change near-term fundamentals but confirms board/auditor continuity.
Journey Medical Corp (DERM) exhibits high volatility with recent short-term gains but a long-term downward trend, reflecting investor skepticism about growth prospects.
Journey Medical reported Q3 2025 earnings with mixed results relative to estimates. The company's key metrics suggest a stable performance, but the lack of significant beat or miss indicates limited immediate trading impact.
The reported Q3 losses and revenue lag suggest potential challenges ahead, possibly affecting investor confidence and stock valuation.
The announcement could positively influence the dermatology sector, potentially benefiting DERM stock.
alphai scores every news story that mentions DERM with an AI model for sentiment and relevance, and aggregates insider trades from Journey Medical Corp's SEC EDGAR Form 4 filings. Figures refresh continuously.
Journey Medical Corp (DERM) filed an SEC Form 8-K — Submission of Matters to a Vote of Security Holders. false 0001867066 0001867066 2026-06-24 2026-06-24 iso4217:USD xbrli:shares iso4217:USD xbrli:shares UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of repor
2 min readJourney Medical Corp (DERM) is experiencing a period of high volatility, with recent short-term gains but a long-term downward trend. The company's stock performance over the past year shows a significant decline, reflecting skepticism about its growth and financial management despite some analyst "buy" ratings from smaller firms. Investors are advised to be cautious, as the stock sits at an inflection point, requiring clear evidence of sustained revenue growth and operational improvements to justify a higher valuation.
3 min readWhile the top- and bottom-line numbers for Journey Medical (DERM) give a sense of how the business performed in the quarter ended September 2025, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.
3 min readJourney Medical (DERM) delivered earnings and revenue surprises of -12.50% and -0.39%, respectively, for the quarter ended September 2025. Do the numbers hold clues to what lies ahead for the stock?
3 min readCompany to host conference call to discuss financial results and provide a corporate update on November 12, 2025 at 4:30 p.m. ET Company to host conference call to discuss financial results and provide a corporate update on November 12, 2025 at 4:30 p.m. ET ...
4 min readFDA-approved Emrosi ( 40 mg Minocycline Hydrochloride Modified-Release Capsules, 10 mg immediate release and 30 mg extended release ) is available in the United States for the treatment of inflammatory lesions of rosacea in adults
2 min readFDA-approved Emrosi ( 40 mg Minocycline Hydrochloride Modified-Release Capsules, 10 mg immediate release and 30 mg extended release ) is available in the United States for the treatment of inflammatory lesions of rosacea in adults ...
3 min readDERM, HOPE and NXRT have been added to the Zacks Rank #5 (Strong Sell) List on September 4, 2025.
2 min readSCOTTSDALE, Ariz., Aug. 18, 2025 ( GLOBE NEWSWIRE ) -- Journey Medical Corporation DERM ( "Journey Medical," "the Company," "we" or "our" ) , a commercial-stage pharmaceutical company primarily focused on selling and marketing FDA-approved prescription pharmaceutical products for the treatment ...
3 min readSCOTTSDALE, Ariz., Aug. 18, 2025 ( GLOBE NEWSWIRE ) -- Journey Medical Corporation ( Nasdaq: DERM ) ( "Journey Medical," "the Company," "we" or "our" ) , a commercial-stage pharmaceutical company primarily focused on selling and marketing FDA-approved prescription pharmaceutical products for the ...
3 min read
